Download Champions' latest AACR 2025 Poster
High-throughput screening of clinically relevant patient-derived 3D cultures to inform on the efficacy of Antibody Drug Conjugate Payloads in 10 distinct cancer indications
Antibody-drug conjugates (ADCs) are a promising class of targeted cancer therapies, but assessing their efficacy across diverse tumor types requires robust, scalable, and clinically relevant models. Traditional 2D cultures fall short in replicating tumor heterogeneity and microenvironmental context, limiting translational impact.
Champions Oncology developed a high-throughput screening (HTS) platform using patient-derived 3D cultures from its Champions TumorGraft3D (CTG3D) platform. These models are derived from over 165 well-characterized PDX lines spanning 10 cancer types and miniaturized into a 384-well plate format, enabling cost-effective, scalable drug screening.
Champions Oncology developed a high-throughput screening (HTS) platform using patient-derived 3D cultures from its Champions TumorGraft3D (CTG3D) platform. These models are derived from over 165 well-characterized PDX lines spanning 10 cancer types and miniaturized into a 384-well plate format, enabling cost-effective, scalable drug screening.
- CTG3D cultures were screened with ADC payloads like SN-38 and Exatecan across multiple cancer types. Luciferase-based viability assays confirmed robust growth, reproducibility, and pharmacological responsiveness.
- Assay quality metrics (Z' factor, S:N ratio) confirmed consistency across replicates. Drug sensitivity (IC50) data aligned with molecular features (e.g., ABCB1 expression) in parental PDXs, supporting model fidelity and translational relevance.
- This miniaturized 3D model platform enables efficient screening and mechanistic investigation of ADC payloads, representing a powerful tool for accelerating preclinical drug discovery and prioritizing candidates for clinical development.
Download the Poster